Acadia files regulatory application for trofinetide to treat Rett syndrome in EU. The company also outlines other pipeline goals for 2025-2026.

Acadia’s first drug, Nuplazid (pimavanserin), is approved in the United States for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. In the past year ...

Researchers from the Cleveland Clinic Genome Center have successfully applied advanced artificial intelligence (AI) genetics ...

Patients living with Parkinson’s disease are encouraged to engage in regular exercise to help manage symptoms and improve ...

This link suggests that Parkinson’s may have digestive origins, and by addressing gastrointestinal health, it may be possible to prevent or delay the onset of neurological symptoms. The role of ...

Mark Giaquinto was diagnosed with Parkinson's disease five years ago and continues to combat the illness with a positive outlook.

an estimated 153,000 people are living with a Parkinson's diagnosis in the UK as of 2023. While tremors and slow movement are the main symptoms of Parkinson's disease, studies have shown a symptom ...

Previously the devices were set to a standard strength and frequency, but because Parkinson’s symptoms can vary throughout the day – with tremors often worse in the morning and when a patient ...

Blood Test Could Predict Parkinson's Seven Years Before Symptoms June 18, 2024 — Scientists have developed a simple blood test that uses artificial intelligence (AI) to predict Parkinson's up to ...

Bladder-related symptoms are urgency, incontinence and night-time frequency. It is advised to rule out other causes of an enlarged prostate by a healthcare provider. Parkinson’s disease ...